Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Management of Cancer Pain

Management of Cancer Pain Cancer pain management necessitates the use of opioids when pain is moderate or severe. Opioids need to be versatile and effective. Newer formulations may improve patient compliance and may be more conducive to the management of transient flares of pain; they also may be tailored to treat certain special populations and may be particularly effective in certain clinical situations. For example, newer opioids have been developed for transdermal, nasal, and nebulized administration, providing a ‘needle-less’ means of controlling pain in those unable to take oral medications. However, newer opioid formulations are not a substitute for good pain management strategies and will not control pain unless provided in adequate doses and schedules. Newer opioid formulations have niche roles in clinical practice, and pain and palliative specialists need to be aware of new developments in opioids and delivery systems. This state-of-the-art review provides a synopsis of recent advances and evolving technologies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Management of Cancer Pain

Davis, Mellar
American Journal of Cancer , Volume 5 (3) – Aug 10, 2012
Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/management-of-cancer-pain-ykEzFEIdN0
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605030-00004
Publisher site
See Article on Publisher Site

Abstract

Cancer pain management necessitates the use of opioids when pain is moderate or severe. Opioids need to be versatile and effective. Newer formulations may improve patient compliance and may be more conducive to the management of transient flares of pain; they also may be tailored to treat certain special populations and may be particularly effective in certain clinical situations. For example, newer opioids have been developed for transdermal, nasal, and nebulized administration, providing a ‘needle-less’ means of controlling pain in those unable to take oral medications. However, newer opioid formulations are not a substitute for good pain management strategies and will not control pain unless provided in adequate doses and schedules. Newer opioid formulations have niche roles in clinical practice, and pain and palliative specialists need to be aware of new developments in opioids and delivery systems. This state-of-the-art review provides a synopsis of recent advances and evolving technologies.

Journal

American Journal of Cancer – Springer Journals

Published: Aug 10, 2012

References

  • Epidemiology of cancer pain and factors influencing poor pain control
    Davis, M.P.; Walsh, D.
  • Errors in opioid prescribing: a prospective survey [abstract]
    Estfan, B.; Shaheen, P.; Walsh, D.
  • Opioids in cancer pain: common dosing errors
    Kochhar, R.; LeGrand, S.B.; Walsh, D.
  • Look before leaping; combined opioids may not be the rave
    Davis, M.P.; LeGrand, S.B.; Lagman, R.
  • Opioid dose titration for severe cancer pain: a systematic evidence based review
    Davis, M.P.; Weissman, D.E.; Arnold, R.M.
  • Central control of breathing mammals: neuronal circuitry, membrane properties, and neurotransmitters
    Bianchi, A.L.; Denavit, S. D.; Champagnat, J.
  • Bedside perspectives on the use of opioids: transferring results of clinical research into practice
    Ravenscroft, P.; Schneider, J.
  • Controversies in pharmacotherapy of pain management
    Davis, M.P.; Walsh, D.; Lagman, R.
  • Morphine and alternative opioids in cancer pain: the EAPC recommendations
    Hanks, G.W.; Conno, F.; Cherny, N.
  • Opioid rotation in cancer patients: pros and cons
    Estfan, B.; LeGrand, S.B.; Walsh, D.
  • Opioid purchases and expenditures in nine Western European countries: “Are we killing off morphine?”
    DeConno, F.; Ripamonti, C.; Brunelli, C.
  • National survey of hospital patients
    Bruster, S.; Jarman, B.; Bosanquet, N.
  • Psychosocial and pharmacologic predictors of satisfaction with intravenous patient-controlled analgesia
    Jamison, R.N.; Taft, K.; O’Hara, J.P.
  • Preoperative emotional states in patients with breast cancer and postoperative pain
    Ozlap, G.; Sarioglu, R.; Tuncel, G.
  • Role of psychosocial factors in postoperative pain control and recovery with patient-controlled analgesia
    Perry, F.; Parker, R.K.; White, P.F.
  • Symptom control in advanced cancer: important drugs and routes of administration
    Walsh, D; Doona, M; Molnar, M
  • Contribution to variability in response to opioids
    Hanks, G.W.; Reid, C.
  • The panorama of opioid-related cognitive dysfunction in patients with cancer
    Lawlor, P.G.
  • Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain
    Mao, J.; Mayer, D.J.
  • Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?
    King, T.; Ossipov, M.H.; Vanderah, T.W.
  • Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery
    Gardell, L.R.; King, T.; Ossipov, M.H.
  • Pain facilitatory circuits in the mammalian central nervous system: their behavioral significance and role in morphine analgesic tolerance
    McNally, G.P.
  • Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity
    Laulin, J.P.; Celerier, E.; Larcher, A.
  • Evidence for opiate-activated NMDA processes masking opiate analgesia in rats
    Celerier, E.; Laulin, J.P.; Larcher, A.
  • Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance
    Xie, J.Y.; Herman, D.A.; Stiller, C.O.
  • Neuronal plasticity: increasing the gain in pain
    Woolf, C.J.; Salter, M.W.
  • Plasticity: downstream of glutamate
    Kind, P.C.; Neumann, P.E.
  • Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain
    Ru-Rong, J.; Woolf, C.J.
  • Opioid induced abnormal pain sensitivity
    Mao, J.
  • Clinical experience with diamorphine in advanced malignant disease
    Twycross, R.G.
  • Methadone in the management of intractable neuropathic noncancer pain
    Moulin, D.E.; Palma, D.; Watling, C.
  • Oral opioid therapy for chronic peripheral and central neuropathic pain
    Rowbotham, M.C.; Twilling, L.; Davies, P.S.
  • Are opioids effective in relieving neuropathic pain?
    Dellemijn, P.
  • Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence
    Elkadar, A.; Sproule, B.
  • Buprenorphine: how to use it right
    Johnson, R.E.; Strain, E.C.; Amass, L.
  • Effects of buprenorphine versus buprenorphine/naloxone tables in non-dependent opioid abuser
    Strain, E.C.; Stoller, K.; Walsh, S.L.
  • Acute pain management for patients receiving maintenance methadone or buprenorphine therapy
    Alford, D.P.; Compton, P.; Samet, J.H.
  • Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review
    Chou, R.; Clark, E.; Helfand, M.
  • Opioid formulations: tailoring to the needs in chronic pain
    Reder, R.
  • Sustained relief of chronic pain: pharmacokinetics of sustained release morphine
    Gourlay, G.K.
  • Retrospective analysis of Kadian (morphine sulfate sustained release capsules) in patients with chronic nonmalignant pain
    Chao, J.
  • Comparison of once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain
    Broomhead, A.; Kerr, R.; Tester, W.
  • Comparative study of morphine diffusion from sustained release polymeric suspensions
    Morales, M.E.; Gallardo, L.V.; Calpena, A.C.
  • Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid
    Takatori, T.; Yamamoto, K.; Yamaguchi, T.
  • Pharmacokinetics of two novel rectal controlled-release morphine formulations
    Babul, N.; Darke, A.C.; Anslow, J.A.
  • The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate release 30mg rectal suppositories and controlled-release 30mg oral tablets
    Kaiko, R.F.; Fitzmartin, R.D.; Thomas, G.B.
  • Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain
    Bruera, E.; Fainsinger, R.; Spachynski, K.
  • Control efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain
    Moolenaar, F.; Meijler, W.J.; Frijlink, H.W.
  • Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials
    Grosset, A.; Roberts, M.; Woodson, M.
  • Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol
    Malonne, H.; Sonet, B.; Streel, B.
  • Buprenorphine in cancer pain
    Davis, M.
  • Buprenorphine tablets versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms
    Chawarski, M.C.; Moody, D.E.; Pakes, J.
  • Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials
    Ciraulo, D.A.; Hitzemann, R.J.; Somoza, E.
  • Single opioids administration modifies gonadal steroids in both the CNS and plasma of male rats
    Ceccarelli, I.; Pavado, A.M.; Fiorenzani, P.
  • Buprenorphine induces ceiling in respiratory depression but not analgesia
    Dahan, A.; Yassen, A.; Romberg, R.
  • Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation
    Megarbane, B.; Marie, N.; Pirnay, S.
  • Sublingual buprenorphine is effective in the treatment of chronic pain syndrome
    Malinoff, H.L.; Barkin, R.L.; Wilson, G.
  • Single-dose comparison of buprenorphine 0.3 and 0.6mg iv given after operation: clinical effects and plasma concentrations
    Watson, P.J.Q.; McQuay, H.J.; Bullingham, R.E.S.
  • Multidose/observational, comparative clinical analgesic evaluation of buprenorphine
    Mok, M.S.; Lippmann, M.; Steen, S.N.
  • Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets
    Adams, M.; Ahdieh, H.
  • Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
    Adams, M.A.; Pieneaszek, H.J.; Gammaitoni, A.R.
  • Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study
    Adams, M.; Ahdieh, H.
  • Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study
    Gabrail, N.; Dvergste, C.; Ahdieh, H.
  • Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study
    Sloan, P.; Slatkin, N.; Ahdieh, N.
  • Opioids in cancer pain
    Davis, M.P.
  • Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons
    Choi, D.W.; Peters, S.; Viseskul, V.
  • Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids
    Church, J.; Lodge, D.; Berry, S.C.
  • The role of dextromethorphan in pain control
    Weinbroum, A.A.; Rudick, V.; Paret, G.
  • Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis
    Pechnick, R.; Poland, R.
  • Dextromethorphan O-demethylation polymorphism in an African-American population
    He, N.; Daniel, H.I.; Hajiloo, L.
  • The polymorphic metabolism of dextromethorphan
    Woodworth, J.R.; Dennis, S.R.; Moore, L.
  • MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance
    Galer, B.S.; Lee, D.; Ma, T.
  • Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-flunaltrexamine
    Adams, J.U.; Paronis, C.A.; Holtzman, S.G.
  • Opioids in cancer pain
    Davis, M.P.
  • Tramadol relieves pain and allodynia in polyneuropathy: a randomized, double-blind, controlled-trial
    Sindrup, S.H.; Andersen, G.; Madsen, C.
  • Opioids in cancer pain
    Davis, M.P.
  • The role of tramadol in cancer pain treatment: a review
    Leppert, W.; Luczak, J.
  • Tramadol: present and future
    Shipton, E.A.
  • Clinical pharmacology of tramadol
    Grond, S.; Sablotzki, A.
  • Tramadol: focus on musculoskeletal and neuropathic pain
    Mattia, C.; Coluzzi, F.
  • Nasal administration of opioids for pain management in adults
    Dale, O.; Hjortkjaer, R.; Kharasch, D.
  • Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer
    Davis, G.A.; Rudy, A.C.; Archer, S.M.
  • Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief
    Toussaint, S.; Maidl, J.; Schwagmeier, R.
  • A new formulation of nasal fentanyl spray for postoperative analgesia: a pilot study
    Paech, M.J.; Lim, C.B.; Banks, S.L.
  • Intranasal fentanyl titration for postoperative pain management in an unselected population
    Striebel, H.W.; Pommerening, J.; Rieger, A.
  • Disposition of nasal, intravenous, and oral methadone in healthy volunteers
    Dale, O.; Hoffer, C.; Pamela, S.
  • Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients
    Fitzgibbon, D.; Morgan, D.; Dockter, D.
  • A randomized crossover trial of patient controlled intranasal fentanyl and oral morphine for procedural wound care in adult patients with burns
    Finn, J.; Wright, J.; Fong, J.
  • Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers
    Coda, B.A.; Rudy, A.C.; Archer, S.M.
  • Intranasal delivery of morphine
    Ilium, L.; Watts, P.; Fisher, A.N.
  • Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer
    Pavis, H.; Wilcock, A.; Edgecombe, J.
  • Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone
    Takala, A.; Kaasalainen, V.; Seppala, T.
  • Intranasal absorption of buprenorphine: in vivo bioavailability study n sheep
    Lindhardt, K.; Ravn, C.; Gizurarson, S.
  • Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain
    Zeppetella, G.
  • Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impadion pain model: a randomized, double blind, placebo-controlled, parallel-group study
    Wermeling, D.P.; Grant, G.M.; Lee, A.
  • Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects
    Masood, A.R.; Thomas, S.H.
  • Inhaled fentanyl as a method of analgesia [letter]
    Worsley, M.H.; MacLeod, A.D.; Brodie, M.J.
  • Pharmacokinetics of inhaled liposome-encapsulated fentanyl
    Hung, O.R.; Whynot, S.C.; Varvel, J.R.
  • Pulmonary administration of aerosolized fentanyl: pharmacokinetic analysis of systemic delivery
    Mather, L.E.; Woodhouse, A.; Ward, M.E.
  • Nebulized fentanyl for relief of abdominal pain
    Bartfield, J.M.; Flint, R.D.; McErlean, M.
  • Design and in vitro evaluation of new drug-in-adhesive formulations of fentanyl transdermal patches
    Mehdizadeh, A.; Toliate, T.; Rouini, M.
  • Dermal penetration of fentanyl: inter-and intraindividual variations
    Larsen, R.H.; Nielsen, F.; Sorensen, J.A.
  • Transdermal delivery of fentanyl by electroporation I. Influence of electrical factors
    Vanbever, R.; LeBoulenge, E.; Preat, V.
  • Transdermal delivery of fentanyl: rapid onset of analgesia using skin electroporation
    Vanbever, R.; Langers, G.; Monmayeur, S.
  • The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat
    Ashburn, M.A.; Ogden, L.L.; Zhang, J.
  • Reproducible fentanyl doses delivered intermittently at different time intervals from an electro transport system
    Gupta, S.K.; Sathyan, G.; Phipps, B.
  • Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil
    Roy, S.D.; Flynn, G.L.
  • Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients
    Solassol, I.; Caumette, L.; Bressolle, F.
  • Fentanyl remaining in a transdermal system following three days of continuous use
    Marquardt, K.A.; Tharratt, R.S.; Musallam, N.A.
  • Old dog: new (ma)trix
    Budd, K.; Collett, B.J.
  • Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications
    Sathyan, G.; Guo, C.; Sivakumar, L.
  • Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design
    Roy, S.D.; Gutierrez, M.; Flynn, G.
  • The effect of dosing frequency on the pharmacokinetics of a fentanyl HCI patient-controlled transdermal system (PCTS)
    Sathyan, G.; Zomorodi, K.; Gidwani, S.
  • The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial
    Chelly, J.E.; Grass, J.; Houseman, T.W.
  • The fentanyl HC1 patient-controlled transdermal fentanyl system (PCTS) an alternative to intravenous patient controlled analgesia in the postoperative setting
    Sinatra, R.
  • Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial
    Viscusi, E.R.; Reynolds, L.; Chung, F.
  • Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCI patient-controlled transdermal system (PCTS)
    Gupta, S.K.; Hwang, S.; Southam, M.
  • Transdermal buprenorphine
    Evans, H.C.; Easthope, S.E.
  • Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label uncontrolled, prospective observational clinical study
    Muriel, C.; Failde, I.; Mico, J.A.
  • Transdermal buprenorphine in the treatment of chronic pain
    Sittl, R.
  • Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and non cancer pain: results of a retrospective cohort study
    Sittl, R.; Likar, R.; Poulsen Nautrup, B.
  • Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for seven days [abstract]
    Reidenberg, B.; El-Tahtawy, A.; Munera, C.
  • Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to seven days [abstract]
    Reidenberg, B.; El-Tahtawy, A.; Munera, C.
  • Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification
    Sobel, B.-F.; Sigmon, S.C.; Walsh, S.L.
  • Evaluation of an injection depot formulation of buprenorphine: placebo comparison
    Sigmon, S.C.; Wong, C.J.; Chausmer, A.L.
  • Safety assessment of encapsulated morphine delivered epidurally in a sustained-release multivesicular liposome preparation in dogs
    Yaksh, T.L.; Provencher, J.C.; Rathbun, M.L.